GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magenta Therapeutics Inc (NAS:MGTA) » Definitions » PB Ratio

Magenta Therapeutics (Magenta Therapeutics) PB Ratio : 0.57 (As of May. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Magenta Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-05), Magenta Therapeutics's share price is $0.6996. Magenta Therapeutics's Book Value per Share for the quarter that ended in Jun. 2023 was $1.23. Hence, Magenta Therapeutics's PB Ratio of today is 0.57.

The historical rank and industry rank for Magenta Therapeutics's PB Ratio or its related term are showing as below:

MGTA' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 4.92
Current: 0.6

During the past 7 years, Magenta Therapeutics's highest PB Ratio was 4.92. The lowest was 0.00. And the median was 0.00.

MGTA's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.5 vs MGTA: 0.60

During the past 12 months, Magenta Therapeutics's average Book Value Per Share Growth Rate was -48.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -20.10% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Magenta Therapeutics was -12.20% per year. The lowest was -20.10% per year. And the median was -16.15% per year.

Back to Basics: PB Ratio


Magenta Therapeutics PB Ratio Historical Data

The historical data trend for Magenta Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Magenta Therapeutics PB Ratio Chart

Magenta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PB Ratio
Get a 7-Day Free Trial 1.30 4.22 2.64 1.51 0.23

Magenta Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.69 0.23 0.62 0.62

Competitive Comparison of Magenta Therapeutics's PB Ratio

For the Biotechnology subindustry, Magenta Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Magenta Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Magenta Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Magenta Therapeutics's PB Ratio falls into.



Magenta Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Magenta Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2023)
=0.6996/1.23
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Magenta Therapeutics  (NAS:MGTA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Magenta Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Magenta Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Magenta Therapeutics (Magenta Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
100 Technology Square, 5th Floor, Cambridge, MA, USA, 02139
Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, MGTA-45 and others.
Executives
Peter Evan Harwin director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Tomas Kiselak director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Edward Carr officer: CHIEF ACCOUNTING OFFICER 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Ryan Savitz officer: CHIEF FINANCIAL OFFICER 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Lei Meng director 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Simrat Randhawa officer: Chief Medical Officer 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Avidity Partners Management Lp director 2828 N HARWOOD STREET, SUITE 1220, DALLAS TX 75201
Marino Garcia director, officer: CEO and President C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVENUE, SUITE 2012, NEW YORK NY 10170
Adam M Veness officer: See Remarks C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Moulder Leon O Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paula Soteropoulos director 49 WINONA STREET, PEABODY MA 01960
Jonathan Violin director 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Third Rock Ventures Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Michael Vasconcelles director C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140

Magenta Therapeutics (Magenta Therapeutics) Headlines